We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $581M
1-Year Est. Return 373.68%
This Fund
S&P 500
This Quarter Est. Return
+35.36%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$3.5M
Cap. Flow
-$20.2M
Cap. Flow %
-5.33%
Top 10 Hldgs %
57.24%
Holding
101
New
34
Increased
16
Reduced
11
Closed
39

Top Buys

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$15.7M
2
ROIV icon
Roivant Sciences
ROIV
+$14.9M
3
CRNX
Crinetics Pharmaceuticals
CRNX
+$14.5M
4
CABA icon
Cabaletta Bio
CABA
+$11.9M
5
IMVT icon
Immunovant
IMVT
+$11.1M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$11.8M
2
ACLX
Arcellx
ACLX
+$11M
3
MRUS
Merus
MRUS
+$10.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$10.3M
5
MRK icon
Merck
MRK
+$9.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Miscellaneous 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAM
51
CALL
DELISTED
Avidity Biosciences
RNAM
$184K 0.05%
+75,000
New +$1.18M
CRNX
52
PUT
DELISTED
Crinetics Pharmaceuticals
CRNX
$158K 0.04%
+175,000
New +$6.85M
ACLX
53
PUT
DELISTED
Arcellx
ACLX
$135K 0.04%
+50,000
New +$3.17M
BHVN icon
54
PUT
Biohaven
BHVN
$2.37B
$122K 0.03%
+30,000
New +$1.49M
FOLD
55
CALL
DELISTED
Amicus Therapeutics
FOLD
$120K 0.03%
+400,000
New +$5.12M
VERA icon
56
PUT
Vera Therapeutics
VERA
$2.59B
$75K 0.02%
+40,000
New +$1.43M
KRYS icon
57
PUT
Krystal Biotech
KRYS
$10.6B
$71K 0.02%
+20,000
New +$2.78M
AUTL
58
CALL
Autolus Therapeutics
AUTL
$596M
$68.8K 0.02%
+250,000
New +$1.56M
ROIV icon
59
PUT
Roivant Sciences
ROIV
$25.2B
$56.3K 0.01%
+750,000
New +$8.09M
TARS icon
60
PUT
Tarsus Pharmaceuticals
TARS
$3.98B
$41.3K 0.01%
+50,000
New +$1.47M
TARA icon
61
CALL
Protara Therapeutics
TARA
$233M
$13.2K ﹤0.01%
+87,900
New +$284K
UTHR icon
62
CALL
United Therapeutics
UTHR
$20.9B
$10.8K ﹤0.01%
+10,000
New +$2.26M
ACIU icon
63
AC Immune
ACIU
$284M
– –
-434,588
Closed -$2.17M
ACLX
64
CALL
DELISTED
Arcellx
ACLX
– –
-623
Closed -$283K
AMLX icon
65
Amylyx Pharmaceuticals
AMLX
$3.8B
– –
-83,381
Closed -$1.23M
ANIP icon
66
ANI Pharmaceuticals
ANIP
$1.64B
– –
-85,382
Closed -$4.71M
ARGX icon
67
CALL
argenx
ARGX
$64.6B
– –
-26,484
Closed -$10.1M
ARKG icon
68
PUT
ARK Genomic Revolution ETF
ARKG
$2B
– –
-5,000
Closed -$375K
ARWR icon
69
Arrowhead Research
ARWR
$12.2B
– –
-59,038
Closed -$1.81M
BBIO icon
70
BridgeBio Pharma
BBIO
$14.6B
– –
-253,948
Closed -$10.3M
CYTK icon
71
Cytokinetics
CYTK
$10.1B
– –
-24,111
Closed -$2.01M
ETNB
72
DELISTED
89bio
ETNB
– –
-408,257
Closed -$4.56M
EYPT icon
73
EyePoint Inc
EYPT
$395M
– –
-95,732
Closed -$2.21M
FATE icon
74
Fate Therapeutics
FATE
$297M
– –
-898,196
Closed -$3.36M
IBB icon
75
PUT
iShares Biotechnology ETF
IBB
$10.6B
– –
-2,000
Closed -$360K
1 2
3
4 5

Similar funds

PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
Cambridge Advisors Omaha, Nebraska $582M AUM 19.14% 1-Year Est. Return

Stempoint Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Stempoint Capital held 101 positions worth $378M, up 0.93% from $375M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Stempoint Capital withdrew a net $20.2M in Q1 2024, closing 39 positions and reducing 11 holdings. Its most notable exit was Protagonist Therapeutics, an estimated $11.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 92% a quarter earlier, followed by Miscellaneous.

Against the trend, Stempoint Capital opened a new position in Tourmaline Bio worth $6.28M.

  • Stempoint Capital's largest Q1 2024 buy was Tourmaline Bio: 274,219 shares worth $6.28M.
  • Stempoint Capital added most to Autolus Therapeutics in Q1 2024, an estimated $15.7M increase.
  • Stempoint Capital's biggest Q1 2024 reduction was Arcellx, cutting an estimated $11M.
  • Stempoint Capital fully exited Protagonist Therapeutics in Q1 2024, selling an estimated $11.8M.
  • Stempoint Capital's ten largest holdings make up 57% of its $378M portfolio in Q1 2024.
  • Stempoint Capital opened 34 new positions and closed 39 in Q1 2024.
  • Stempoint Capital's portfolio value rose 0.93% quarter-over-quarter to $378M.

Based on Stempoint Capital's 13F filing for Q1 2024, filed 14 May 2024.